The bullish breakout in these stocks suggests the housing market has turned a corner
With U.S. housing starts perking up, investors may be looking at an early entry point for a broad recovery for home builders and their stocks.
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
Bitcoin bulls avoided a correction as US markets opened, but analysis warned that Strategy was responsible for much of the latest BTC price strength.
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse ArticlesWith U.S. housing starts perking up, investors may be looking at an early entry point for a broad recovery for home builders and their stocks.
Net selling from altcoins topped $209 billion, far outpacing the sell volumes seen during Bitcoin's five-month sell-off. Will these traders reposition into...
International markets have been outperforming their American rivals recently. Investors could still be in the early innings of a years-long trend.
New research says targeted immigration policies can address workforce shortages and support the U.S. population as it ages.
Goldman Sachs CEO David Solomon reveals he owns Bitcoin - Bloomberg
Sai Launches Perps Platform Combining CEX Speed with Onchain Settlement
Andy Constan says the rest of the world now offers more opportunities.
BofA offers art consulting to wealthy clients as collectors increase loans demand
W P Carey stock falls after pricing $432 million equity offering
Investing.com -- Arista Networks shares are down 2.9% in premarket trading on Wednesday after Meta Platforms and Nvidia announced a long-term partnership t...
Bayer retreats as investors sour on deal to settle Roundup litigation
Moleculin Biotech stock rises as AML drug trial shows promising results